A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing.
4 affiliations
- 1Great Ormond Street Institute of Child Health, University College London, London, UK.
- 2Department of Clinical Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- 3Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.
- 4Department of Microbiology, Great Ormond Street Hospital for Children, London, UK.
Abstract
Background
Amikacin is widely used in paediatric patients, but developmental changes in drug disposition from birth through to adolescence make dose optimization challenging. Existing population pharmacokinetic (PopPK) models are typically developed for specific paediatric age groups, limiting their applicability across the full paediatric age range.Objectives
To develop a unified paediatric PopPK model of amikacin capable of predicting drug concentrations from birth to 18 years of age and to evaluate its suitability for model-informed dosing.Methods
Retrospective therapeutic drug monitoring data were obtained from 409 paediatric patients receiving intravenous amikacin at a tertiary children's hospital. A PopPK model was developed using data from 204 neonates, which incorporated mechanistic covariates describing growth and renal maturation, including allometric body-weight scaling, postmenstrual age (PMA), postnatal age (PNA) and age-adjusted serum creatinine. Predictive performance was evaluated for 205 older patients aged 1 month to 18 years, and compared with previously published paediatric amikacin PopPK models. The model developed using the neonatal data was subsequently refitted to the combined dataset to obtain the final parameter estimates.Results
A two-compartment model adequately described amikacin pharmacokinetics. Clearance was influenced by body weight, PMA, PNA, age-adjusted serum creatinine and concomitant glycopeptide use. The model developed in neonates using mechanistic maturation and renal function covariates successfully predicted amikacin concentrations in older paediatric patients and showed lower prediction bias and improved precision than previously published paediatric amikacin models. The final parameter estimates were obtained by fitting the model developed on neonates to all patients.Conclusions
A maturation-informed PopPK model successfully predicted amikacin concentrations from birth to 18 years and provides a unified framework for model-informed precision dosing across the paediatric age range.
Related
- Population Pharmacokinetics and Model-Informed Precision Dosing of Colistin Sulfate in Critically Ill Patients with Carbapenem-Resistant Gram-Negative Infections: A Prospective Pharmacokinetic-Pharmacodynamic Study.
- External evaluation of population pharmacokinetic models for tacrolimus in kidney transplant recipients: implications for model-informed precision dosing.
- Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity
- Electronic-Nomogram-Guided Micafungin Dosing Regimen in Critically Ill Patients: A Population Pharmacokinetic Study
- Development and validation of a cefepime population pharmacokinetic model to guide treatment for patients with hospital-acquired pneumonia requiring renal replacement
BibTeX
@article{alabdulkarim2026unified,
title = {{A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing.}},
author = {Najla Alabdulkarim and Charlotte Barker and Bairavi Indrakumar and James Hatcher and Orlagh McGarrity and Timothy Best and Iek Leng Cheng and Joseph F Standing},
journal = {The Journal of antimicrobial chemotherapy},
year = {2026},
month = oct,
doi = {10.1093/jac/dkag354},
url = {https://europepmc.org/article/MED/42910747},
note = {CC BY},
}
RIS
TY - JOUR
TI - A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing.
AU - Najla Alabdulkarim
AU - Charlotte Barker
AU - Bairavi Indrakumar
AU - James Hatcher
AU - Orlagh McGarrity
AU - Timothy Best
AU - Iek Leng Cheng
AU - Joseph F Standing
PY - 2026
DA - 2026/10/01
JO - The Journal of antimicrobial chemotherapy
DO - 10.1093/jac/dkag354
UR - https://europepmc.org/article/MED/42910747
AB - Background Amikacin is widely used in paediatric patients, but developmental changes in drug disposition from birth through to adolescence make dose optimization challenging. Existing population pharmacokinetic (PopPK) models are typically developed for specific paediatric age groups, limiting their applicability across the full paediatric age range.Objectives To develop a unified paediatric PopPK model of amikacin capable of predicting drug concentrations from birth to 18 years of age and to evaluate its suitability for model-informed dosing.Methods Retrospective therapeutic drug monitoring data were obtained from 409 paediatric patients receiving intravenous amikacin at a tertiary children's hospital. A PopPK model was developed using data from 204 neonates, which incorporated mechanistic covariates describing growth and renal maturation, including allometric body-weight scaling, postmenstrual age (PMA), postnatal age (PNA) and age-adjusted serum creatinine. Predictive performance was evaluated for 205 older patients aged 1 month to 18 years, and compared with previously published paediatric amikacin PopPK models. The model developed using the neonatal data was subsequently refitted to the combined dataset to obtain the final parameter estimates.Results A two-compartment model adequately described amikacin pharmacokinetics. Clearance was influenced by body weight, PMA, PNA, age-adjusted serum creatinine and concomitant glycopeptide use. The model developed in neonates using mechanistic maturation and renal function covariates successfully predicted amikacin concentrations in older paediatric patients and showed lower prediction bias and improved precision than previously published paediatric amikacin models. The final parameter estimates were obtained by fitting the model developed on neonates to all patients.Conclusions A maturation-informed PopPK model successfully predicted amikacin concentrations from birth to 18 years and provides a unified framework for model-informed precision dosing across the paediatric age range.
SN - 0305-7453
SN - 1460-2091
ER -